Anna Biosciences Launches Pioneering Immunotherapeutic Treatment to Fight COVID-19
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem.
The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease.
Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem Platform represents a significant new tool in the arsenal against these rapidly evolving diseases.
With today’s announcement, Anna Biosciences underscores both its initial successes in the lab and the successful patenting of the Syntem Platform. The company is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market.
The Syntem Platform also shows strong promise for use against cancer and other pathogens. Research into the application of Syntem for oncological targets is currently underway. The resulting therapies could offer precision targeting, and the potential to mitigate side effects while being easier to administer to patients.
“Like vaccines in the 20th century, synthetic small molecule immunotherapy is on the precipice of advancing human health in untold ways. A powerful new tool is on the horizon in our fight against coronaviruses. And that’s just the beginning of this technology’s potential,” said Dr. Anthony Rullo, a scientific co-founder of Anna Biosciences and assistant professor of medicine at McMaster University in Ontario, Canada. “I’m extremely proud of our team, and the extraordinary effort of everyone involved at Anna Biosciences in the furthering of this technology.”
About Anna Biosciences
Anna Biosciences is a drug discovery company that uses decentralized partnerships to develop and advance new therapies for better patient outcomes. Anna Biosciences’ first initiative, the Syntem Platform, is developing proprietary molecules to trigger synthetic immunity for COVID-19 and beyond.
Anna Biosciences will continue to develop the Syntem Platform modality for additional therapies for a range of diseases. The company is currently working on the implementation of this approach to activate immune cells that can recognize and attack cancers.
For more information, visit http://annabiosciences.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005353/en/
Contact information
Media Contact:
Risha Tyagi
Racepoint Global
annabiosciences@racepointglobal.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT to Shape the Future of AI and Cloud on a Global Scale in Collaboration with NVIDIA23.4.2024 09:22:00 CEST | Press release
Global leading IT firm FPT today announced a comprehensive strategic partnership with NVIDIA, aiming to offer a one-stop shop for AI & Cloud consisting of AI products, GPU infrastructure, tech experts, and domain expertise for clients in Vietnam and all FPT’s presence areas. This endeavor will be attained by establishing AI factories for AI research and development in the region, expanding advanced AI and cloud capabilities on a global scale, and fostering a future-ready workforce in technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422007290/en/ The MoU signing ceremony took place in Hanoi, Vietnam, with the participation of FPT and NVIDIA senior executives (Photo: Business Wire) FPT plans to invest USD 200 million in building an AI factory that will serve as a sovereign cloud. These will feature NVIDIA’s latest technologies, including NVIDIA AI Enterprise software and frameworks and NVIDIA H100 Tensor Core GPUs
Peking University Emerges Victorious in 2024 ASC Student Supercomputer Challenge Finals23.4.2024 09:02:00 CEST | Press release
On April 13, 2024, the 2024 ASC Student Supercomputer Challenge (ASC24) Finals drew to a close at Shanghai University after five days of intense competition. Peking University emerged as the undisputed overall champion, securing their place in ASC Student Supercomputer Challenge history. After ASC24 registration opened on November 16, 2023, over 300 teams from universities participated in the intense preliminary contests. As a result, the absolute best 25 teams ascended to the finals hosted at Shanghai University from April 9 to 13, 2024. This marked a groundbreaking moment in ASC history, with the highest number of teams ever qualifying for onsite finals since the competition's inception in 2012. During the finals, teams showcased their skills by designing and building cluster systems capped at a maximum power consumption of 3,000 W. They tackled a lineup of cutting-edge scientific and engineering applications, including HPL and HPCG benchmarks, Large Language Model (LLM), OpenCAEPoro
LatticeFlow AI Joins the U.S. AI Safety Institute Consortium23.4.2024 09:00:00 CEST | Press release
LatticeFlow AI, the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC). LatticeFlow AI researchers will support Working Group #3, focusing on capability evaluations. Together with the National Institute of Standards & Technology (NIST) and other consortium members, LatticeFlow AI will support the development of methods, benchmarks, and testing environments that help organizations operationalize the practices outlined in NIST’s AI Risk Management Framework (RMF). Dave Henry, SVP of Business Development at LatticeFlow AI, added: “AI safety programs are interdisciplinary in nature, requiring a broad range of management and technical skills to execute. The Consortium brings diverse experts together to create durable and innovative practices that promote trustworthy AI. We look forward to contributing our knowledge of AI model safety and c
Regula Pinpoints Top Three Business Challenges with Verification of International Customers23.4.2024 09:00:00 CEST | Press release
In addition to the clear risks, such as an increase in fraud, attracting new foreign customers presents less apparent challenges, including the absence of standardized documentation and language barriers. These are the results of a global survey conducted by Regula, a global developer of forensic devices and identity verification solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423489077/en/ Top problems businesses deal with when verifying foreign IDs, according to Regula’s survey (Graphic: Business Wire) Key challenges for businesses When it comes to identity verification for international customers, including a growing community of digital nomads, organizations from various industries participating in Regula’s survey tend to point out the following challenges: The lack of unified document standards. 41% of decision-makers in all sectors report a significant challenge due to the lack of standardized identity doc
Manhattan Associates Named a Leader in 2024 Gartner ® Magic Quadrant™ for Transportation Management Systems for the Sixth Consecutive Year23.4.2024 09:00:00 CEST | Press release
Manhattan Associates Inc. (NASDAQ: MANH), a global leader in supply chain commerce solutions, announced today that it has been named a Leader in the Gartner Magic Quadrant for Transportation Management Systems for the sixth consecutive year. Manhattan Active® Transportation Management (TM) also ranks among the three highest ranked vendors in the Level 3 Complexity, Level 4 Complexity and Level 5 Complexity Use Cases in the accompanying Critical Capabilities report. As supply chains grow in complexity, enterprises are looking to better orchestrate transportation and distribution processes with a unified supply chain execution solution. Industry experts agree that Manhattan’s cloud-native technology architecture and unified supply chain platform distinguishes Manhattan Active TM. This solution breaks down supply chain execution silos to deliver real-time visibility into shipments, offers predictive analytics for better decision-making, delivers the ability to automate manual processes an